Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-7977 + Ribavirin in Treatment-Naive HCV Genotype 1
NCT01441180Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sofosbuvir in hepatitis C (HCV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Participants With Adverse Events at 24 weeks and Sustained Virologic Response. Started Sep 2011; status: completed.
02
Drugs
sofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01441180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01441180.